Targeting cell cycle and hormone receptor pathways in cancer

C. E.S. Comstock, M. A. Augello, J. F. Goodwin, R. De Leeuw, M. J. Schiewer, W. F. Ostrander, Richard Burkhart, A. K. McClendon, P. A. McCue, E. J. Trabulsi, C. D. Lallas, L. G. Gomella, M. M. Centenera, J. R. Brody, L. M. Butler, W. D. Tilley, K. E. Knudsen

Research output: Contribution to journalArticle

Abstract

The cyclin/cyclin-dependent kinase (CDK)/retinoblastoma (RB)-axis is a critical modulator of cell cycle entry and is aberrant in many human cancers. New nodes of therapeutic intervention are needed that can delay or combat the onset of malignancies. The antitumor properties and mechanistic functions of PD-0332991 (PD; a potent and selective CDK4/6 inhibitor) were investigated using human prostate cancer (PCa) models and primary tumors. PD significantly impaired the capacity of PCa cells to proliferate by promoting a robust G 1 -arrest. Accordingly, key regulators of the G 1 -S cell cycle transition were modulated including G1 cyclins D, E and A. Subsequent investigation demonstrated the ability of PD to function in the presence of existing hormone-based regimens and to cooperate with ionizing radiation to further suppress cellular growth. Importantly, it was determined that PD is a critical mediator of PD action. The anti-proliferative impact of CDK4/6 inhibition was revealed through reduced proliferation and delayed growth using PCa cell xenografts. Finally, first-in-field effects of PD on proliferation were observed in primary human prostatectomy tumor tissue explants. This study shows that selective CDK4/6 inhibition, using PD either as a single-agent or in combination, hinders key proliferative pathways necessary for disease progression and that RB status is a critical prognostic determinant for therapeutic efficacy. Combined, these pre-clinical findings identify selective targeting of CDK4/6 as a bona fide therapeutic target in both early stage and advanced PCa and underscore the benefit of personalized medicine to enhance treatment response.

Original languageEnglish (US)
Pages (from-to)5481-5491
Number of pages11
JournalOncogene
Volume32
Issue number48
DOIs
Publication statusPublished - Nov 28 2013
Externally publishedYes

    Fingerprint

Cite this

Comstock, C. E. S., Augello, M. A., Goodwin, J. F., De Leeuw, R., Schiewer, M. J., Ostrander, W. F., ... Knudsen, K. E. (2013). Targeting cell cycle and hormone receptor pathways in cancer. Oncogene, 32(48), 5481-5491. https://doi.org/10.1038/onc.2013.83